Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Mallinckrodt
Fuji
Argus Health
Deloitte
Johnson and Johnson
Daiichi Sankyo
AstraZeneca
Harvard Business School
US Army

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,205,082

« Back to Dashboard

Which drugs does patent 9,205,082 protect, and when does it expire?

Patent 9,205,082 protects TARGINIQ and is included in one NDA.

This patent has forty-six patent family members in twenty-seven countries.
Summary for Patent: 9,205,082
Title:Opioid agonist/antagonist combinations
Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
Inventor(s): Kaiko; Robert F. (Weston, CT), Colucci; Robert D. (Newtown, CT)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Application Number:14/214,659
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Delivery; Use; Formulation;

Drugs Protected by US Patent 9,205,082

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-001 Jul 23, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. ➤ Sign Up
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-002 Jul 23, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. ➤ Sign Up
Purdue Pharma Lp TARGINIQ naloxone hydrochloride; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 205777-003 Jul 23, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,205,082

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,277,384 Opioid agonist/antagonist combinations ➤ Sign Up
6,696,066 Opioid agonist/antagonist combinations ➤ Sign Up
8,673,355 Opioid agonist/antagonist combinations ➤ Sign Up
9,474,750 Opioid agonist/opioid antagonist/acetaminophen combinations ➤ Sign Up
7,172,767 Opioid agonist / antagonist combinations ➤ Sign Up
7,749,542 Opioid agonist/antagonist combinations ➤ Sign Up
8,822,487 Opioid agonist/opioid antagonist/acetaminophen combinations ➤ Sign Up
8,105,631 Opioid agonist/antagonist combinations ➤ Sign Up
7,419,686 Opioid agonist/antagonist combinations ➤ Sign Up
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,205,082

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200001942 ➤ Sign Up
Slovenia 2266564 ➤ Sign Up
Slovenia 1685839 ➤ Sign Up
Slovenia 1041987 ➤ Sign Up
Russian Federation 2241458 ➤ Sign Up
Serbia 50070 ➤ Sign Up
Yugoslavia 39400 ➤ Sign Up
Portugal 2266564 ➤ Sign Up
Portugal 1685839 ➤ Sign Up
Portugal 1041987 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Covington
Cerilliant
McKinsey
Dow
Harvard Business School
Citi
Accenture
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot